Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-10-10

Clinical Trial Update: An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer [Phase 2]

View source ↗

Summary

This update reports efficacy and safety data from a Phase 2 trial of Erdafitinib in participants with urothelial cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BALVERSA (erdafitinib)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Urothelial Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-10-10